{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:14Z","timestamp":1789056434453,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201789","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:15:08Z","timestamp":1781828108000},"page":"201789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sindbis virus self-amplifying replicon is compatible with modified nucleotides mediating expression and vaccine responses in vivo"],"prefix":"10.1016","volume":"34","author":[{"given":"Hiva","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Agbayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Dudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McCluskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-7193","authenticated-orcid":false,"given":"Bassel","family":"Akache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201789_bib1","article-title":"An Update on Self-Amplifying mRNA Vaccine Development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omta.2026.201789_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines - self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omta.2026.201789_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201789_bib4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"de Alwis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201789_bib5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201789_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202508907","article-title":"Divergent Delivery and Expression Kinetics of Lipid and Polymeric Nanoparticles across mRNA Modalities","volume":"12","author":"Casmil","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omta.2026.201789_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omta.2026.201789_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omta.2026.201789_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201789_bib10","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1038\/s41467-024-51301-0","article-title":"N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation","volume":"15","author":"Monroe","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201789_bib11","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical basis for stabilizing messenger RNA through secondary structure design","volume":"49","author":"Wayment-Steele","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201789_bib12","article-title":"Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study","volume":"4","author":"Akahata","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omta.2026.201789_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugae004","article-title":"Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo","volume":"1","author":"Azizi","year":"2024","journal-title":"NAR Mol. Med."},{"key":"10.1016\/j.omta.2026.201789_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","article-title":"Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency","volume":"43","author":"McGee","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201789_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108964","article-title":"Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine","volume":"27","author":"Aboshi","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omta.2026.201789_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","article-title":"Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection","volume":"18","author":"Erasmus","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201789_bib17","article-title":"Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine","volume":"17","author":"Komori","year":"2025","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.omta.2026.201789_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68617-y","article-title":"1m\u03a8 influences the performance of various positive-stranded RNA virus-based replicons","volume":"14","author":"Miyazato","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201789_bib19","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201789_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/vaccines11071142","article-title":"Advances in saRNA Vaccine Research against Emerging\/Re-Emerging Viruses","volume":"11","author":"Liu","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.omta.2026.201789_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-1-0716-0795-4_30","article-title":"The Quantification of Antigen-Specific T Cells by IFN-\u03b3 ELISpot","volume":"2183","author":"Akache","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201789_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/978-1-0716-0795-4_31","article-title":"Measurement of Antigen-Specific IgG Titers by Direct ELISA","volume":"2183","author":"Akache","year":"2021","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:15:40Z","timestamp":1789053340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001242"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201789","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sindbis virus self-amplifying replicon is compatible with modified nucleotides mediating expression and vaccine responses in vivo","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201789"}}